◉ New study · May 21, 2026  ·  Pharmacist-reviewed
PuraVigor  /  Journal  /  Magnesium + arterial stiffness — AJCN 2026
Cardiovascular · Negative result

Magnesium and arterial stiffness in diabetes: 'no effect'.

A double-blind, placebo-controlled randomized trial published in the American Journal of Clinical Nutrition (May 2026) tested whether 6 months of 350 mg/day magnesium citrate would slow arterial calcification and reduce arterial stiffness in 74 older adults with type 2 diabetes. The answer: no measurable effect on either outcome. Here is what to make of a clean negative trial — and why it actually matters for your daily magnesium routine.

MAGNESIUM / cardiovascular RESULT
/ no effect
Study type
RCT, double-blind
Sample size / trials
74 adults · 6 months
Journal
The American Journal of Clinical Nutrition
Published
2026 May

§.01The study, in one paragraph.

74 adults with type 2 diabetes (78% male, median age 72) with documented peripheral medial arterial calcification (MAC) and high baseline arterial stiffness (cfPWV ≥ 12.0 m/s) were randomized to either 350 mg/day of oral magnesium citrate or placebo for 6 months. Outcomes were measured by carotid-femoral pulse wave velocity (the gold standard for arterial stiffness) and nephelometry-based serum calciprotein crystallization (a marker of how readily calcium phosphate precipitates in serum, which links to MAC). It was double-blind, placebo-controlled, and registered with the Dutch trial registry and ISRCTN.

§.02What the numbers actually show.

Six months of 350 mg/day magnesium citrate did not reduce calciprotein crystallization. It did not reduce arterial stiffness. Both outcomes were statistically indistinguishable from placebo. The authors conclude that, "Daily supplementation of 350 mg appears to be ineffective in this population, possibly attributable to normomagnesemia and preserved renal function."

That last bit is the key piece. The study population was not magnesium-deficient at baseline — their renal function was preserved, their serum magnesium was normal. So adding more magnesium to a system that already has enough did not move arterial calcification.

§.03What it means for your magnesium routine.

This is a clean negative trial, and it lands in a specific lane: older diabetic patients with already-normal magnesium status do not get cardiovascular benefit from adding more magnesium. It does not say magnesium is useless — it says the population that already has enough magnesium will not see arterial calcification regress from extra supplementation.

Where the magnesium cardiovascular story still holds:

For everyone else taking magnesium daily: the rationale is not arterial calcification reversal. It is everything else magnesium does well — sleep, stress, muscle cramps, daily mineral adequacy.

§.04Limitations the authors flagged.

§.05Where it fits in the broader evidence.

This is the cleanest negative trial on magnesium + arterial stiffness to date. It fits with the broader pattern: most magnesium intervention trials show benefit primarily in populations with measurable deficiency. The Zhang 2016 meta-analysis on magnesium and blood pressure showed a modest 2-3 mmHg systolic effect overall, but the larger effects were in deficient subgroups.

The takeaway is consistent with our editorial position: measure first, supplement to correct. Magnesium is not a generic "more is better" intervention. It is a corrective tool for specific situations. Generic daily supplementation for "heart health" via this mechanism is not supported by AJCN-quality evidence.


§.99The bottom line.

Six months of 350 mg/day magnesium citrate did not move arterial stiffness or calciprotein crystallization in older diabetic adults who started with normal magnesium status. That is useful information. It does not contradict the reasons most people take magnesium — sleep, stress, cramps, daily mineral adequacy — but it does push back on the broader 'magnesium for cardiovascular calcification' narrative. If your goal is sleep or stress, glycinate at 200-400 mg/day stays a reasonable choice. If your goal is arterial health via supplementation, AJCN says: not from this protocol.

Related on the apothecary

Magnesium glycinate, 90 capsules — at the apothecary.


§.RXThe study.

Magnesium supplementation did not reduce serum calciprotein crystallization and arterial stiffness in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Author group, AJCN 2026 — The American Journal of Clinical Nutrition, 2026 May

Reviewed by Dr. Marthe Janssen, PharmD on May 21, 2026. We summarize peer-reviewed research without making medical claims.

Disclaimer: this article is educational only and not medical advice. Statements about supplements have not been evaluated by the FDA. Always discuss new supplements with your prescriber.